FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 311:1528-1533 December 13, 1984 Number 24 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

In an effort to clarify the role of immunosuppressive drugs in the management of lupus nephritis, we pooled data from all published clinical trials in which patients had been randomly assigned to receive either prednisone alone or prednisone plus cyclophosphamide or azathioprine. The pooled analysis showed that patients receiving immunosuppressive drugs had less renal deterioration (P = 0.006), were less likely to have end-stage renal disease (P = 0.023), and were less likely to die from kidney disease (P = 0.024) than patients receiving steroids alone. There were no significant differences with respect to deaths from nonrenal causes or overall mortality. When cyclophosphamide and azathioprine were considered separately, both were associated with a 40 per cent reduction in the rates of adverse renal outcomes, although because the treatment groups were smaller, many of these differences were not statistically significant. A power analysis showed that a study of 100 high-risk patients (development of renal insufficiency in 50 per cent) would be needed to prove that an immunosuppressive agent is 50 per cent superior to steroids alone in preventing renal deterioration. We conclude that immunosuppressive drugs and steroids together are more effective than steroids alone in treating lupus nephritis and that published trials have reached false negative conclusions because of small sample sizes.

This article has been cited by other articles:

• Bargman, J. M. (2008). How did cyclophosphamide become the drug of choice for lupus nephritis?. Nephrol Dial Transplant 0: gfn640v1-gfn640 [Full Text]  
• Katz, J. N., Losina, E. (2007). J.N. Katz and E. Losina comment on the above letters:. JBJS 89: 2548-2550 [Full Text]  
• Ranchin, B., Fargue, S. (2007). Review: New treatment strategies for proliferative lupus nephritis: keep children in mind!. Lupus 16: 684-691 [Abstract]  
• Zhu, B., Chen, N., Lin, Y., Ren, H., Zhang, W., Wang, W., Pan, X., Yu, H. (2007). Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 22: 1933-1942 [Abstract] [Full Text]  
• Liu, C.-P., Kuo, Y.-C., Shen, C.-C., Wu, M.-H., Liao, J.-F., Lin, Y.-L., Chen, C.-F., Tsai, W.-J. (2007). (S)-Armepavine inhibits human peripheral blood mononuclear cell activation by regulating Itk and PLC{gamma} activation in a PI-3K-dependent manner. J. Leukoc. Biol. 81: 1276-1286 [Abstract] [Full Text]  
• Ponticelli, C. (2006). New Therapies for Lupus Nephritis. CJASN 1: 863-868 [Full Text]  
• Correale, J., Fiol, M. (2004). Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 63: 2363-2370 [Abstract] [Full Text]  
• Houssiau, F. A. (2004). Management of Lupus Nephritis: An Update. J. Am. Soc. Nephrol. 15: 2694-2704 [Full Text]  
• Mok, C C, Wong, R W S, Lai, K N (2003). Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis 62: 799-804 [Abstract] [Full Text]  
• Fraenkel, L, Bogardus, S T Jr, Wittink, D R (2003). Risk-attitude and patient treatment preferences. Lupus 12: 370-376 [Abstract]  
• Cortes-Herandez, J, Ordi-Ros, J, Labrador, M, Segarra, A, Tovar, J L, Balada, E, Vilardell-Tarres, M (2003). Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 12: 287-296 [Abstract]  
• Ballardie, F. W., Roberts, I. S. D. (2002). Controlled Prospective Trial of Prednisolone and Cytotoxics in Progressive IgA Nephropathy. J. Am. Soc. Nephrol. 13: 142-148 [Abstract] [Full Text]  
• Lewis, E. J. (2001). The Treatment of Lupus Nephritis: Revisiting Galen. ANN INTERN MED 135: 296-298 [Full Text]  
• Adu, D. (2001). The evidence base for the treatment of lupus nephritis in the new millennium. Nephrol Dial Transplant 16: 1536-1538 [Full Text]  
• Ward, M. M. (2000). Changes in the Incidence of End-stage Renal Disease Due to Lupus Nephritis, 1982-1995. Arch Intern Med 160: 3136-3140 [Abstract] [Full Text]  
• Daimon, S., Saga, T., Nakayama, M., Nomura, Y., Chikaki, H., Dan, K., Koni, I. (2000). Dextran sulphate cellulose columns for the treatment of nephrotic syndrome due to inactive lupus nephritis. Nephrol Dial Transplant 15: 235-238 [Full Text]  
• Amano, H, Morimoto, S, Kaneko, H, Tokano, Y, Takasaki, Y, Hashimoto, H (2000). Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers. Lupus 9: 26-32 [Abstract]  
• Gaubitz, M., Schorat, A., Schottel, H., Kern, P., Domschke, W. (1999). Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 8: 731-736 [Abstract]  
• Moore, A. D, Joseph, L. (1999). Sample size considerations for superiority trials in systemic lupus erythematosus (SLE). Lupus 8: 612-619 [Abstract]  
• Bono, L., Cameron, J.S., Hicks, J.A. (1999). The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 92: 211-218 [Abstract] [Full Text]  
• CAMERON, J. S. (1999). Lupus Nephritis. J. Am. Soc. Nephrol. 10: 413-424 [Full Text]  
• Mittal, G, Balakrishna, C, Mangat, G, Joshi, V R (1999). 'Sustained remission' in a case of SLE following megadose cyclophosphamide. Lupus 8: 77-80 [Abstract]  
• Dooley, M A, Falk, R J (1998). Immunosuppressive therapy of lupus nephritis. Lupus 7: 630-634 [Abstract]  
• Hricik, D. E., Chung-Park, M., Sedor, J. R. (1998). Glomerulonephritis. NEJM 339: 888-899 [Full Text]  
• Hanly, J.G., Hong, C., Zayed, E., Jones, J.V., Jones, E. (1995). Immunomodulating effects of synchronised plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus. Lupus 4: 457-463 [Abstract]  
• Arce-Salinas, C.A., Villa, A.R., Martinez-Rueda, J.O., Munoz, L., Cardiel, M.H., Alcocer-Varela, J., Alarcon-Segovia, D. (1995). Factors associated with chronic renal failure in 121 patients with diffuse proliferative lupus nephritis: a case-control study. Lupus 4: 197-203 [Abstract]  
• Belmont, H M., Storch, M., Buyon, J., Abramson, S. (1995). New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 4: 104-108 [Abstract]  
• Donadio, J. JR, Hart, G., Bergstralh, E., Holley, K. (1995). Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 4: 109-115 [Abstract]